Baxter and bioMérieux Get CE Mark for Nephroclear CCL14 Test for Kidney Injury

Baxter International and bioMérieux have received a CE mark for their Nephroclear CCL14 test, which is used to predict persistent severe acute kidney injury.

This type of injury is a sudden decrease in kidney function over a period of hours to days, often as a result of illness, trauma or infection. The sudden loss of kidney function leads to the accumulation of toxins and fluid in the blood that, if left untreated, can be fatal.

The companies plan to launch the test commercially in Europe in 2022 to support treatment of kidney patients.